Oritavancin: Difference between revisions
From IDWiki
(Imported from text file) |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
= Oritavancin = |
|||
== Classification == |
|||
* Semisynthetic lipoglycopeptide antibiotic with very long half-life |
* Semisynthetic lipoglycopeptide antibiotic with very long half-life |
||
| Line 17: | Line 13: | ||
* Not required |
* Not required |
||
[[Category:Lipoglycopeptides]] |
|||
== Adverse Events == |
|||
Latest revision as of 20:09, 31 January 2020
- Semisynthetic lipoglycopeptide antibiotic with very long half-life
Indications
- MRSA skin and soft tissue infections
Dosing
- IV once a week, long-acting
Renal Dosing
- Not required
